TNFSF15 is an independent predictor for the development of Crohn's disease-related complications in Koreans

Journal of Crohn's and Colitis

Volumn 8, Issue 10, 2014, Pages 1315-1326

  Yang, Dong Hoon ^a   Yang, Suk Kyun ^a   Song, Kyuyoung ^a   Hong, Myunghee ^a   Park, Sang Hyoung ^a   Lee, Ho Su ^a   Kim, Ji Beom ^a   Lee, Hyo Jeong ^a   Park, Soo Kyung ^a   Jung, Kee Wook ^a   Kim, Kyung Jo ^a   Ye, Byong Duk ^a   Byeon, Jeong Sik ^a   Myung, Seung Jae ^a   Kim, Jin Ho ^a   Shin, Ui Sup ^b   Yu, Chang Sik ^a   Lee, Inchul ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Complication; Crohn's disease; Single nucleotide polymorphism; TNFSF15

Indexed keywords

GENOMIC DNA; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; TNFSF15 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ALLELE; ANUS DISEASE; ANUS FISTULA; ANUS STRICTURE; ARTICLE; CHILD; CROHN DISEASE; CROSS-SECTIONAL STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOTE; HUMAN; INTESTINE RESECTION; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; NON PERIANAL PENETRATING COMPLICATION; PHENOTYPE; REOPERATION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SURGICAL DRAINAGE; TNFSF15 GENE; ANTAGONISTS AND INHIBITORS; COMPLICATION; CONSTRICTION, PATHOLOGIC; GENETICS; INTESTINE; MIDDLE AGED; PATHOLOGY; RECTAL FISTULA; SOUTH KOREA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CONSTRICTION, PATHOLOGIC; CROHN DISEASE; FEMALE; GENOTYPE; HUMANS; INTESTINES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECTAL FISTULA; REOPERATION; REPUBLIC OF KOREA; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84908260866     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.04.002     Document Type: Article

References (36)

1. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
2. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
3. Hampe J., Franke A., Rosenstiel P., Till A., Teuber M., Huse K., et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007, 39:207-211.
4. Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463.
5. Franchimont D., Vermeire S., El Housni H., Pierik M., Van Steen K., Gustot T., et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004, 53:987-992.
6. Hong J., Leung E., Fraser A.G., Merriman T.R., Vishnu P., Krissansen G.W. TLR2, TLR4 and TLR9 polymorphisms and Crohn's disease in a New Zealand Caucasian cohort. J Gastroenterol Hepatol 2007, 22:1760-1766.
7. Yamazaki K., McGovern D., Ragoussis J., Paolucci M., Butler H., Jewell D., et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 2005, 14:3499-3506.
8. Yang S.K., Lim J., Chang H.S., Lee I., Li Y., Liu J., et al. Association of TNFSF15 with Crohn's disease in Koreans. The American journal of gastroenterology 2008, 103:1437-1442.
9. Giallourakis C., Stoll M., Miller K., Hampe J., Lander E.S., Daly M.J., et al. IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn disease and identification of a novel association with ulcerative colitis. Am J Hum Genet 2003, 73:205-211.
10. Lees C.W., Barrett J.C., Parkes M., Satsangi J. New IBD genetics: common pathways with other diseases. Gut 2011, 60:1739-1753.
11. Jostins L., Ripke S., Weersma R.K., Duerr R.H., McGovern D.P., Hui K.Y., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
12. Ahmad T., Armuzzi A., Bunce M., Mulcahy-Hawes K., Marshall S.E., Orchard T.R., et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002, 122:854-866.
13. Cuthbert A.P., Fisher S.A., Mirza M.M., King K., Hampe J., Croucher P.J., et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002, 122:867-874.
14. Hampe J., Grebe J., Nikolaus S., Solberg C., Croucher P.J., Mascheretti S., et al. Association of NOD2 (CARD15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002, 359:1661-1665.
15. Vermeire S., Wild G., Kocher K., Cousineau J., Dufresne L., Bitton A., et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 2002, 71:74-83.
16. Abreu M.T., Taylor K.D., Lin Y.C., Hang T., Gaiennie J., Landers C.J., et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002, 123:679-688.
17. Economou M., Trikalinos T.A., Loizou K.T., Tsianos E.V., Ioannidis J.P. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004, 99:2393-2404.
18. Prescott N.J., Fisher S.A., Franke A., Hampe J., Onnie C.M., Soars D., et al. A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. Gastroenterology 2007, 132:1665-1671.
19. Glas J., Seiderer J., Wetzke M., Konrad A., Torok H.P., Schmechel S., et al. rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS One 2007, 2:e819.
20. Tremelling M., Cummings F., Fisher S.A., Mansfield J., Gwilliam R., Keniry A., et al. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology 2007, 132:1657-1664.
21. Thiebaut R., Kotti S., Jung C., Merlin F., Colombel J.F., Lemann M., et al. TNFSF15 polymorphisms are associated with susceptibility to inflammatory bowel disease in a new European cohort. The American journal of gastroenterology 2009, 104:384-391.
22. Franke A., McGovern D.P., Barrett J.C., Wang K., Radford-Smith G.L., Ahmad T., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010, 42:1118-1125.
23. Latiano A., Palmieri O., Latiano T., Corritore G., Bossa F., Martino G., et al. Investigation of multiple susceptibility loci for inflammatory bowel disease in an Italian cohort of patients. PLoS One 2011, 6:e22688.
24. Kakuta Y., Kinouchi Y., Negoro K., Takahashi S., Shimosegawa T. Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease. Gut 2006, 55:1527-1528.
25. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl. A):5-36.
26. Yang S.K., Jung Y., Hong M., Kim H., Ye B.D., Lee I., et al. No association between TNFSF15 and IL23R with ulcerative colitis in Koreans. J Hum Genet 2011, 56:200-204.
27. Picornell Y., Mei L., Taylor K., Yang H., Targan S.R., Rotter J.I. TNFSF15 is an ethnic-specific IBD gene. Inflamm Bowel Dis 2007, 13:1333-1338.
28. Cleynen I., Gonzalez J.R., Figueroa C., Franke A., McGovern D., Bortlik M., et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. Gut 2013, 62:1556-1565.
29. Cosnes J., Cattan S., Blain A., Beaugerie L., Carbonnel F., Parc R., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250.
30. Thia K.T., Sandborn W.J., Harmsen W.S., Zinsmeister A.R., Loftus E.V. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010, 139:1147-1155.
31. Lovasz B.D., Lakatos L., Horvath A., Szita I., Pandur T., Mandel M., et al. Evolution of disease phenotype in adult and pediatric onset Crohn's disease in a population-based cohort. World J Gastroenterol 2013, 19:2217-2226.
32. Henckaerts L., Van Steen K., Verstreken I., Cleynen I., Franke A., Schreiber S., et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009, 7(e2):972-980.
33. Panaccione R., Colombel J.F., Sandborn W.J., Rutgeerts P., D'Haens G.R., Robinson A.M., et al. Adalimumab sustains clinical remission and overall clinical benefit after 2years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010, 31:1296-1309.
34. Peyrin-Biroulet L., Oussalah A., Williet N., Pillot C., Bresler L., Bigard M.A. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011, 60:930-936.
35. Jones D.W., Finlayson S.R. Trends in surgery for Crohn's disease in the era of infliximab. Ann Surg 2010, 252:307-312.
36. Yang S.K., Yun S., Kim J.H., Park J.Y., Kim H.Y., Kim Y.H., et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008, 14:542-549.